Biliary-tract cancer: improving therapy by adding molecularly targeted agents
- PMID: 22192730
- DOI: 10.1016/S1470-2045(11)70329-1
Biliary-tract cancer: improving therapy by adding molecularly targeted agents
Comment on
-
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.Lancet Oncol. 2012 Feb;13(2):181-8. doi: 10.1016/S1470-2045(11)70301-1. Epub 2011 Dec 20. Lancet Oncol. 2012. PMID: 22192731 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical